Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 8/2008

01.08.2008 | original article

Salvage Gastrectomy Following a Combination of Biweekly Paclitaxel and S-1 for Stage IV Gastric Cancer

verfasst von: Sumiya Ishigami, Shoji Natsugoe, Akihiro Nakajo, Masataka Matsumoto, Yoshikazu Uenosono, Takaaki Arigami, Tetsuro Setoyama, Hideo Arima, Yasuto Uchikado, Yoshiaki Kita, Ken Sasaki, Takashi Aikou

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Background and aim

We investigated the clinical benefits of salvage gastrectomy for stage IV gastric cancer patients whose distant lesions showed complete response after chemotherapy.

Methods

We enrolled 18 stage IV gastric cancer patients whose distant metastases had disappeared or were controlled by a combination of biweekly paclitaxel (PTX) and S-1. After chemotherapy, these patients received gastrectomy with lymph node dissection. The postoperative outcome was analyzed with respect to both the histological effects of chemotherapy and tumor behavior.

Results

Of the 18 patients, 8 had distant lymph node metastases, 9 had peritoneal dissemination, and five had multiple liver metastases prior to chemotherapy. Fourteen patients received curative surgery (R0). No severe postoperative complications were encountered. Pathological evaluation revealed grade 3 and grade 2 tumor regression in the primary lesion in one and five patients, respectively, and grade 3 and grade 2 tumor regression in the lymph nodes in one and six patients, respectively. Univariate analysis of the patients’ prognosis identified R number, gross tumor type, histological grade of tumor regression, and gender as significant factors. Multivariate analysis showed that only the R number was an independent prognostic factor.

Conclusion

R0 salvage gastrectomy following a combination of biweekly PTX and S-1 may have significant clinical efficacy for advanced gastric cancer patients.
Literatur
1.
Zurück zum Zitat Akiyoshi T, Kawaguchi M, Arinaga S, Miyazaki S, Koba F, Wada T, Tsuji H. Combination chemoimmunotherapy for advanced gastric carcinoma. Jpn J Surg 1984;14:185–190. Medline DOI 10.1007/BF02469566.PubMedCrossRef Akiyoshi T, Kawaguchi M, Arinaga S, Miyazaki S, Koba F, Wada T, Tsuji H. Combination chemoimmunotherapy for advanced gastric carcinoma. Jpn J Surg 1984;14:185–190. Medline DOI 10.​1007/​BF02469566.PubMedCrossRef
2.
Zurück zum Zitat Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991;67:260–265.PubMedCrossRef Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991;67:260–265.PubMedCrossRef
4.
Zurück zum Zitat Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207–2212. Medline DOI 10.1038/sj.bjc.6601413.PubMedCrossRef Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207–2212. Medline DOI 10.​1038/​sj.​bjc.​6601413.PubMedCrossRef
5.
Zurück zum Zitat Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006;94:1130–1135. Medline DOI 10.1038/sj.bjc.6603072.PubMedCrossRef Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006;94:1130–1135. Medline DOI 10.​1038/​sj.​bjc.​6603072.PubMedCrossRef
6.
Zurück zum Zitat Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402–3407. Medline DOI 10.1158/1078-0432.CCR-05-2425.PubMedCrossRef Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402–3407. Medline DOI 10.​1158/​1078-0432.​CCR-05-2425.PubMedCrossRef
7.
Zurück zum Zitat Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–4997. Medline DOI 10.1200/JCO.2006.06.8429.PubMedCrossRef Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–4997. Medline DOI 10.​1200/​JCO.​2006.​06.​8429.PubMedCrossRef
8.
Zurück zum Zitat Hokita S, Aikou T, Miyazono F, Ishigami S, Aridome K, Maenohara S, Saihara T, Suenaga K, Nomura H, Maeda S, Takatori H, Arima H, Uchikado Y, Natsugoe S, Takao S. A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2006;57:736–740. Medline DOI 10.1007/s00280-005-0122-4.PubMedCrossRef Hokita S, Aikou T, Miyazono F, Ishigami S, Aridome K, Maenohara S, Saihara T, Suenaga K, Nomura H, Maeda S, Takatori H, Arima H, Uchikado Y, Natsugoe S, Takao S. A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2006;57:736–740. Medline DOI 10.​1007/​s00280-005-0122-4.PubMedCrossRef
11.
12.
Zurück zum Zitat Yano M, Shiozaki H, Inoue M, Tamura S, Doki Y, Yasuda T, Fujiwara Y, Tsujinaka T, Monden M. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. World J Surg 2002;26:1155–1159. Medline DOI 10.1007/s00268-002-6362-0.PubMedCrossRef Yano M, Shiozaki H, Inoue M, Tamura S, Doki Y, Yasuda T, Fujiwara Y, Tsujinaka T, Monden M. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. World J Surg 2002;26:1155–1159. Medline DOI 10.​1007/​s00268-002-6362-0.PubMedCrossRef
13.
Zurück zum Zitat Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6:159–167. Medline DOI 10.1007/s10120-003-0245-4.PubMedCrossRef Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6:159–167. Medline DOI 10.​1007/​s10120-003-0245-4.PubMedCrossRef
14.
Zurück zum Zitat Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisawa A. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 1997;4:203–208. Medline DOI 10.1007/BF02306611.PubMedCrossRef Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisawa A. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 1997;4:203–208. Medline DOI 10.​1007/​BF02306611.PubMedCrossRef
15.
Zurück zum Zitat Nashimoto A, Yabusaki H, Tanaka O, Sasaki J, Akiyama N. Neoadjuvant chemotherapy in advanced gastric cancer with non-curative factors: a Phase II study with 5-fluorouracil, leucovorin, and cisplatin. Gastric Cancer 1999;2:57–63. Medline DOI 10.1007/s101200050022.PubMedCrossRef Nashimoto A, Yabusaki H, Tanaka O, Sasaki J, Akiyama N. Neoadjuvant chemotherapy in advanced gastric cancer with non-curative factors: a Phase II study with 5-fluorouracil, leucovorin, and cisplatin. Gastric Cancer 1999;2:57–63. Medline DOI 10.​1007/​s101200050022.PubMedCrossRef
16.
Zurück zum Zitat Gallardo-Rincón D, Oñate-Ocaña LF, Calderillo-Ruiz G. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 2000;7:45–50. Medline DOI 10.1007/s10434-000-0045-6.PubMedCrossRef Gallardo-Rincón D, Oñate-Ocaña LF, Calderillo-Ruiz G. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 2000;7:45–50. Medline DOI 10.​1007/​s10434-000-0045-6.PubMedCrossRef
17.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216. Medline DOI 10.1093/jnci/92.3.205.PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216. Medline DOI 10.​1093/​jnci/​92.​3.​205.PubMedCrossRef
18.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1998;1:10–24. Medline.PubMedCrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1998;1:10–24. Medline.PubMedCrossRef
19.
Zurück zum Zitat Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, Fukushima M, Takabayashi A, Sakai Y. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer 2006;9:129–135. Medline DOI 10.1007/s10120-006-0369-4.PubMedCrossRef Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, Fukushima M, Takabayashi A, Sakai Y. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer 2006;9:129–135. Medline DOI 10.​1007/​s10120-006-0369-4.PubMedCrossRef
20.
Zurück zum Zitat Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521–1530. Medline DOI 10.1002/cncr.11660.PubMedCrossRef Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521–1530. Medline DOI 10.​1002/​cncr.​11660.PubMedCrossRef
21.
Zurück zum Zitat Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999;17:2403–2411. Medline.PubMed Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999;17:2403–2411. Medline.PubMed
Metadaten
Titel
Salvage Gastrectomy Following a Combination of Biweekly Paclitaxel and S-1 for Stage IV Gastric Cancer
verfasst von
Sumiya Ishigami
Shoji Natsugoe
Akihiro Nakajo
Masataka Matsumoto
Yoshikazu Uenosono
Takaaki Arigami
Tetsuro Setoyama
Hideo Arima
Yasuto Uchikado
Yoshiaki Kita
Ken Sasaki
Takashi Aikou
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 8/2008
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-008-0539-2

Weitere Artikel der Ausgabe 8/2008

Journal of Gastrointestinal Surgery 8/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.